Bioequivalence study of a valsartan tablet and a capsule formulation after single dosing in healthy volunteers using a replicated crossover design
R. Séchaud1, P. Graf1, H. Bigler1, E. Gruendl2, M. Letzkus1, M. Merz1
1 Novartis Pharma AG, Basel, and 2 SUVA, Luzern, Switzerland
DOI 10.5414/CPP40035
Abstract
Aim: Two formulations of valsartan (Diovan), 320 mg tablets and marketed 160 mg capsules, were evaluated for bioequivalence after single dosing. Methods: The study was designed as a single-center, open-label, 2-treatment, 3-period, repeated-measure (replicated), randomized crossover comparison in 40 healthy volunteers, all of whom completed the study successfully. Valsartan was determined in plasma by HPLC with fluorescence detection after solid-phase extraction. Results: Comparing the new 320 mg tablet with 2 × 160 mg of the marketed valsartan capsules taken at the same time, the ratios of the least square means for AUC0-t, AUCall, AUC0-¥ and Cmax were 1.11, 1.10, 1.10 and 1.09, respectively. The 90% confidence intervals of the AUC and Cmax parameters were within the range of 0.80 – 1.25. Conclusions: Bioequivalence of the new 320 mg tablet with 2 marketed 160 mg capsules was demonstrated.
Author Details
Authors
Departments
- 1 Novartis Pharma AG, Basel, and
- 2 SUVA, Luzern, Switzerland
Address
Dr. R. Séchaud; Novartis Pharma AG, CH-4002 Basel, Switzerland
Email:
[email protected]
Citation
R. Séchaud, P. Graf, H. Bigler, E. Gruendl, M. Letzkus and M. Merz. Bioequivalence study of a valsartan tablet and a capsule formulation after single dosing in healthy volunteers using a replicated crossover design. 2002; 40: 35-40. doi: 10.5414/CPP40035.